Histone deacetylase inhibitors for the treatment of cancer stem cells

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61389030%3A_____%2F16%3A00469858" target="_blank" >RIV/61389030:_____/16:00469858 - isvavai.cz</a>

Result on the web

<a href="http://dx.doi.org/10.1039/c6md00297h" target="_blank" >http://dx.doi.org/10.1039/c6md00297h</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1039/c6md00297h" target="_blank" >10.1039/c6md00297h</a>

Result language

angličtina

Original language name

Histone deacetylase inhibitors for the treatment of cancer stem cells

Original language description

Tiny populations of tumor cells are present in solid and hematologic malignancies and are responsible for cancer development, metastasis and limited response to therapy; these are referred to as cancer stem cells (CSCs). CSCs are resistant to standard cancer treatments and are the main cause of tumor relapse. Therefore, the development of new therapeutics to overcome the resistance of CSCs is greatly required. It is known that epigenetic histone modifications (acetylation/deacetylation) play a crucial role in cancer development through regulation of gene expression. Deacetylation of histone and non-histone proteins controls cell proliferation, metabolism and apoptosis as well as DNA repair and differentiation. Thus, histone deacetylase inhibitors (HDACis) are a promising group of anti-cancer agents, showing the ability to induce growth arrest or apoptosis in tumor cells. In this review, we summarize the current knowledge about the prospects of HDACis utilization in the treatment of CSCs.

Czech name

—

Czech description

—

Type

J_x - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

CEP classification

CC - Organic chemistry

OECD FORD branch

—

Project

<a href="/en/project/LD14128" target="_blank" >LD14128: Synthesis of sirtuin inhibitors</a><br>

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2016

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

MedChemComm

ISSN

2040-2503

e-ISSN

—

Volume of the periodical

7

Issue of the periodical within the volume

12

Country of publishing house

GB - UNITED KINGDOM

Number of pages

15

Pages from-to

2217-2231

UT code for WoS article

000390552300002

EID of the result in the Scopus database

—